

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Prevalence of cortisol cosecretion in patients with primary aldosteronism: role of metanephrine in adrenal vein sampling

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1897585> since 2024-04-29T09:28:44Z

Published version:

DOI:10.1210/clinem/dgad179

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Prevalence of cortisol cosecretion in patients with primary aldosteronism: role of**
2 **metanephrine in adrenal vein sampling**

3
4 Fabrizio Buffolo¹, Jacopo Pieroni^{1*}, Federico Ponzetto^{2*}, Vittorio Forestiero¹, Denis Rossato³,
5 Paolo Fonio³, Antonello Nonnato², Fabio Settanni², Paolo Mulatero¹, Giulio Mengozzi^{2**},
6 Silvia Monticone^{1**}.

7
8 ¹Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences,
9 University of Torino, 10126, Torino, Italy.

10 ²Department of Laboratory Medicine, University of Torino, 10126 Torino, Italy

11 ³Division of Radiology, University of Torino, 10126 Torino, Italy

12 * These authors contributed equally to this work and should be considered as joint second
13 authors.

14 ** These authors contributed equally to this work and should be considered as joint last authors.

15 **Corresponding author:** Prof. Paolo Mulatero Division of Internal Medicine and Hypertension
16 Unit, Department of Medical Sciences, University of Torino, Città della Salute e della Scienza,
17 Via Genova 3, 10126 Torino, Italy. Telephone/Fax number: +39.011.633.6959 /
18 +39.011.633.6931. E-mail: paolo.mulatero@unito.it. ORCID number: 0000-0002-5480-1116

19 Manuscript word count: 2930 excluding references, tables and figure captions.

20 Abstract word count: 240

21 Number of Tables: 1; Number of Figures: 2; 1 Supplemental file.

22 **Source(s) of Funding:** nothing to disclose.

23 **Conflict(s) of Interest/Disclosure(s):** P.M. received fees for educational speech from
24 DIASORIN.

25

1 **Key words:** primary aldosteronism, adrenal venous sampling, metanephrine, cortisol,
2 aldosterone producing adenoma

3

4 **Abstract**

5 *Context*

6 Adrenal venous sampling (AVS) is the gold standard procedure for subtype diagnosis in
7 patients with primary aldosteronism (PA). Cortisol is usually adopted for the normalization of
8 aldosterone levels in peripheral and adrenal samples. However, asymmetrical cortisol secretion
9 can potentially affect the lateralization index, leading to subtype misdiagnosis.

10 *Objective*

11 We aimed to assess the prevalence of asymmetrical cortisol secretion in patients undergoing
12 AVS and whether variations in adrenal vein cortisol might influence AVS interpretations. We
13 then evaluated the use of metanephrines for the normalization of aldosterone levels for
14 lateralization index.

15 *Design, Patient, Setting and Main Outcome Measures*

16 We retrospectively included 101 patients with PA who performed AVS: 49 patients underwent
17 unstimulated AVS, while 52 patients underwent both, unstimulated and cosyntropin stimulated
18 AVS. Eighty-eight patients had bilateral successful AVS according to metanephrine ratio. We
19 assessed the prevalence of asymmetrical cortisol secretion through the cortisol-to-
20 metanephrine (C/M) lateralization index (LI). We then evaluated whether the use of
21 aldosterone-to-metanephrine (A/M) LI can improve the diagnostic accuracy of AVS compared
22 to aldosterone-to-cortisol (A/C) LI.

23

1 *Results*

2 Asymmetrical cortisol secretion is present in 18% of patients with PA. Diagnosis with A/M LI
3 and A/C LI is discordant in 14% of patients: 9% had a diagnosis of UPA with A/M LI instead
4 of BiPA with A/C LI and 5% had a diagnosis of BiPA with A/M LI instead of UPA.

5 *Conclusions*

6 The assessment of metanephrine levels in AVS is useful for the determination of selectivity
7 and lateralization, allowing an accurate diagnosis, especially in patients with asymmetrical
8 cortisol secretion.

9 **Introduction**

10 Primary aldosteronism is the cause of hypertension in about 5-6% of patients in the primary
11 care setting (1–3) and in 10% of patients referred to tertiary centers (4). One third of patients
12 is affected by unilateral and thus surgically curable forms, while two thirds of patients display
13 a bilateral disease, usually treated with mineralocorticoid receptor antagonists (MRAs) (5).
14 Subtype diagnosis is pivotal for the identification of patients that are candidates for unilateral
15 adrenalectomy (6,7). Given the limited accuracy of CT scan for subtype diagnosis (8), current
16 international guidelines recommend adrenal venous sampling (AVS) for subtype definition in
17 the majority of patients with PA (5,7,9). Despite being considered the gold standard test, AVS
18 interpretation is not unequivocal, since in some cases the final diagnosis can change from
19 unstimulated to stimulated procedure (10). Serum cortisol levels, collected from the adrenal
20 veins and inferior vena cava, are conventionally adopted for the definition of adrenal selectivity
21 and for the normalization of aldosterone levels in peripheral and adrenal samples (5,7,9).
22 However, the use of cortisol measurements has some limitations: i- the cortisol secretion is
23 characterized by circadian fluctuations, that makes mandatory the execution of unstimulated
24 AVSs in the early morning, when cortisol production is higher (5,7,9,11); ii- cortisol circulating
25 half-life is relatively high with consequent small step-ups between adrenal and peripheral

1 concentrations, especially for unstimulated procedures (12); iii- cortisol secretion is affected
2 by stress, that can alter the lateralization index when the sampling is performed sequentially
3 with long time-gaps (5); iv- the presence of autonomous cortisol secretion may reduce the
4 cortisol secretion from the contralateral gland below the standard cut-offs that define selectivity
5 (12); v- autonomous cortisol secretion can modify the lateralization indexes and subtype
6 definition (13).

7 Some authors have proposed the use of metanephrines (12,14,15) as a more accurate alternative
8 to define selectivity for AVS procedures. However, the role of aldosterone-to-metanephrine
9 ratio for AVS lateralization has been poorly characterized by previous studies. Moreover, no
10 study has investigated the impact of asymmetrical cortisol secretion on subtype diagnosis of
11 PA.

12 The aim of this study is to evaluate: i- the prevalence of asymmetrical cortisol secretion in PA;
13 ii- whether the presence of asymmetrical cortisol secretion might influence AVS interpretation;
14 iii- the role of the aldosterone-to-metanephrine ratio in AVS for the determination of subtype
15 diagnosis of PA.

17 **Material and Methods**

18 *Study Design and PA diagnosis*

19 We retrospectively included in our study 101 patients referred to the Division of Internal
20 Medicine – Hypertension Unit of the University of Torino, who performed AVS between 2008
21 and 2020. We excluded patients who had performed AVS exclusively with cosyntropin
22 stimulation or with insufficient stocked material for metanephrine assay.

23 PA diagnosis was performed according to the recommendations of the European Society of
24 Hypertension and Endocrine Society (5–7). Screening tests were considered positive with
25 aldosterone-to-renin ratio (ARR) ≥ 30 ng/dL/ng*mL⁻¹*h⁻¹ or aldosterone-to-active renin ratio

1 (AARR) \geq 2.0 ng/dl/mU/l and aldosterone \geq 10 ng/dL. Diagnosis of PA was confirmed by
2 intravenous saline load and/or captopril challenge test in agreement with the guidelines (6,7).
3 Subtype diagnosis was obtained by adrenal computed tomography and AVS, according to ES
4 and ESH recommendations (5,7). AVS were performed with sequential unstimulated
5 catheterization (with $<$ 5 minutes interval between cannulation of the right and the left adrenal
6 vein) in 49 (48.5%) patients and with both, unstimulated and cosyntropin-stimulated procedure,
7 in 52 (51.5%) patients (Table 1). Stimulated procedures were performed under continuous
8 cosyntropin infusion (50 μ g/h, Mayo clinic protocol)(16). Selectivity indices (SI) with C-ratio
9 and M-ratio were defined as $\text{Cortisol}_{\text{adrenal vein}}/\text{Cortisol}_{\text{peripheral vein}}$ and $\text{Metanephrine}_{\text{adrenal}}$
10 $\text{vein}/\text{Metanephrine}_{\text{peripheral vein}}$, respectively. Lateralization indexes (LI) were defined as
11 $(\text{Aldosterone}/\text{Cortisol})_{\text{dominant adrenal vein}}/(\text{Aldosterone}/\text{Cortisol})_{\text{non dominant adrenal vein}}$ (A/C LI),
12 $(\text{Aldosterone}/\text{Metanephrine})_{\text{dominant adrenal vein}}/(\text{Aldosterone}/\text{Metanephrine})_{\text{non dominant adrenal vein}}$
13 (A/M LI) or $(\text{Cortisol}/\text{Metanephrine})_{\text{dominant adrenal vein}}/(\text{Cortisol}/\text{Metanephrine})_{\text{non dominant adrenal vein}}$
14 (C/M LI). Contralateral ratio as $(\text{Aldosterone}/\text{Cortisol})_{\text{non dominant adrenal}}$
15 $\text{vein}/(\text{Aldosterone}/\text{Cortisol})_{\text{peripheral vein}}$. Contralateral suppression was defined as contralateral
16 ratio $<$ 1. The analysis for the definition of AVS selectivity were performed using either C-ratio
17 and M-ratio \geq 2 or \geq 3 for unstimulated procedures and C-ratio \geq 5 and M-ratio \geq 3 for cosyntropin
18 stimulated procedures, in agreement with international recommendations (5) and previous
19 reports for the use of metanephrine for selectivity index (14). Patients with bilateral M-ratio \geq 3
20 were considered for the analysis on lateralization indexes. Aldosterone production was
21 considered unilateral with A/C LI \geq 4 and cortisol production with C/M LI \geq 4. The cut-off for
22 A/M LI was derived from A/C LI through univariate linear regression, after exclusion of
23 patients with asymmetrical cortisol secretion.

24

25

1 *Biochemical measurements*

2 Aldosterone concentrations were measured by radioimmunoassay ACTIVE® Aldosterone RIA
3 kit (Beckman Coulter, Brea, CA, USA) and cortisol concentrations were determined by
4 electrochemiluminescence immunoassay with the Elecsys Cortisol II kit (Roche, Basel,
5 Switzerland). Metanephrine concentrations were assessed through liquid chromatography
6 coupled with tandem mass spectrometry detection employing the MassChrom® Free
7 Metanephrines in Plasmakit (Chromsystems Instruments & Chemicals GmbH, Gräfelfing,
8 Germany).

9 Hypercortisolism was investigated by 1-mg dexamethasone suppression test or 24-hour urinary
10 free cortisol in patients with an adrenal nodule ≥ 1 cm at CT scan or with clinical features or
11 comorbidities considered indicative of possible hypercortisolism. Autonomous cortisol
12 secretion was defined by cortisol ≥ 18 $\mu\text{g/L}$ after 1-mg dexamethasone suppression test or 24-
13 hour urinary free cortisol ≥ 150 $\mu\text{g}/24\text{h}$.

14 *Statistical Analysis*

15 Variables were treated as parametric or non-parametric according to their distribution.
16 Categorical variables were expressed as absolute number and percentage. Continuous variables
17 with a normal distribution were expressed as mean \pm standard deviation. Non-normally
18 distributed variables were expressed as median [interquartile range]. We defined the statistical
19 significance by Student *t* test for independent samples of parametric variables and Mann-
20 Whitney U test for non-parametric variables. χ^2 was adopted for comparison of unpaired
21 categorical variables and McNemar's Test for paired categorical variables. We used the Bland-
22 Altman plot to show the relationship between lateralization index defined with A/C-LI and
23 lateralization index defined with A/M-LI. Univariate linear regression was adopted to define
24 the association between A/C-LI and A/M-LI.

25

1 **Results**

2 *Characteristics of patients*

3 Clinical characteristics of patients with PA are summarized in Table 1. Eleven patients had
4 autonomous cortisol secretion, but only one of them had overt hypercortisolism (with 1-mg
5 dexamethasone suppression test $>50 \mu\text{g/L}$). Subtype diagnosis, defined with A/C-LI, was the
6 same using unstimulated or cosyntropin-stimulated procedure in 47 out of 52 AVS (91%)
7 (Figure S1)(17).

8 *Selectivity index*

9 Using C-ratio ≥ 3 , 68 of 101 unstimulated AVS (67%) were bilaterally successful (Figure S2A-
10 B-C) (17). Using M-ratio ≥ 3 , 88 AVSs (87%) were bilaterally successful (Figure S2A-B-D)
11 (17), with consequent 31% increase in bilaterally successful procedures ($p < 0.001$). Using C-
12 ratio ≥ 2 to define selectivity, the number of bilaterally successful AVSs increased up to 76
13 (75%) ($p = 0.005$) (Figure S3A-B-C) (17) and up to 89 (88%) with M-ratio ≥ 2 (Figure S3A-B-
14 D) (17). After cosyntropin stimulation, 50 of 52 (96%) AVSs were considered bilaterally
15 successful with C-ratio ≥ 5 (Figure S4A-B-C) (17), and 52 of 52 (100%) with M-ratio ≥ 3
16 ($p = 0.157$) (Figure S4A-B-D) (17).

18 *Asymmetrical cortisol secretion*

19 We used C/M LI to define cortisol lateralization for 88 unstimulated AVSs that were bilaterally
20 successful according to metanephrine SI. Sixteen of 88 AVSs (18%) showed asymmetrical
21 cortisol secretion (C/M LI ≥ 4) (Figure 1A-C). Nine of them (56%) showed cortisol lateralization
22 on the same side of unilateral PA (UPA), 5 on the opposite side of UPA, and 2 showed
23 asymmetrical cortisol secretion in patients with bilateral PA (BiPA) (Figure 1D).

24 Among the 5 patients with cortisol secretion contralateral to UPA, two had a CT scan showing
25 bilateral nodules, and one patient had overt hypercortisolism with 3 nodules on the side of

1 cortisol lateralization and a normal adrenal gland on the contralateral adrenal where the A/C
2 LI diagnosed lateralized aldosterone production; the remaining two patients had a normal
3 contralateral adrenal gland.

4 Patients with asymmetrical cortisol secretion displayed the greater differences between A/M
5 LI and A/C LI (Figure 1A). After cosyntropin stimulation, C/M LI decreased in all the patients
6 with asymmetrical cortisol secretion (Figure 1B), suggesting a direct stimulation of the
7 contralateral gland, where cortisol secretion is suppressed in unstimulated conditions. No
8 clinical or biochemical differences were observed between patients with symmetrical and
9 asymmetrical cortisol secretion (Table S1) (17). Four of the 16 patients with asymmetrical
10 cortisol secretion had autonomous cortisol secretion diagnosed with biochemical tests (1-mg
11 overnight dexamethasone suppression test and 24-hour urinary free cortisol); the other 12
12 patients were negative at these tests. Seven of the 11 patients with autonomous cortisol
13 secretion displayed symmetrical cortisol secretion ($C/M LI < 4$).

14 *Lateralization index*

15 After exclusion of patients with asymmetrical cortisol secretion, we performed a linear
16 regression to predict A/M LI on the basis of A/C LI (Table S2) (17). An A/C LI of 4,
17 corresponded to 4.3 of A/M LI, that was rounded up to 4 for the following analysis.

18 Twelve of 88 patients (14%) had a different diagnosis with A/M LI vs A/C LI (Figure 2A-B).
19 Eight patients (9%) had a diagnosis of UPA with A/M LI instead of BiPA with A/C LI (Figure
20 2B): 5 have been treated with medical therapy, while 3 underwent adrenalectomy on the basis
21 of the A/C LI after cosyntropin stimulation. All patients who underwent adrenalectomy showed
22 a complete biochemical success after surgery with a histological examination showing a
23 solitary aldosterone producing adenoma (APA) (18).

24 Four patients (5%) had a diagnosis of BiPA with A/M LI instead of UPA with A/C LI (Figure
25 2B). Two of them underwent surgical adrenalectomy with complete biochemical success: at

1 the histological examination one had multiple aldosterone-producing nodules and one a solitary
2 APA (18). One patient refused adrenalectomy. The fourth patient (described in the paragraph
3 *Asymmetrical cortisol secretion*) had overt hypercortisolism. The patient has been treated with
4 adrenalectomy on the side of cortisol lateralization, with complete resolution of
5 hypercortisolism. The biochemical features of PA persisted after surgical treatment consistent
6 with diagnosis of BiPA in agreement with the A/M LI.

7

8 *Cosyntropin effect on A/M LI*

9 In 56% of patients with UPA A/M LI decreased after cosyntropin stimulation, suggesting a
10 stimulation of the contralateral gland (Figure 2C). However, in 44% of patients A/M LI
11 increased after cosyntropin stimulation, suggesting a stimulation of aldosterone secretion from
12 the APA. Compared with patients with reduced A/M LI, patients with increased A/M LI
13 showed a greater increase of peripheral aldosterone levels after cosyntropin stimulation,
14 corroborating the hypothesis of cosyntropin-sensitive APAs (Figure 2D). The effects of
15 cosyntropin infusion on A/M LI changed the subtype diagnosis in 5 patients with UPA (defined
16 with unstimulated A/M LI) to BiPA. On the other side, in 7 patients with BiPA (defined with
17 unstimulated A/M LI) the diagnosis changed to UPA.

18

19 **Discussion**

20 In this study, we evaluated for the first time the presence of asymmetrical cortisol secretion, by
21 the use of C/M LI, in patients with PA and its influence in subtype diagnosis. We then reported
22 how the use of metanephrine normalization, through the use of A/M LI, avoids the biases of
23 asymmetrical cortisol secretion, allowing a more accurate definition of PA subtype.

24 Previous studies investigated the role of metanephrine measurements in AVS as a more
25 sensitive approach for selectivity index, improving the successful rate between 17% to 39%

1 compared with unstimulated AVS (12,14,15). Our study confirmed previous reports, with an
2 increase of 20% for unstimulated AVS and 4% for stimulated procedures.

3 Autonomous cortisol secretion is defined as an alteration of the hypothalamic–pituitary–
4 adrenal axis with increased peripheral cortisol concentration, without the clinical phenotype of
5 overt hypercortisolism (19). Autonomous cortisol secretion is assessed by various tests,
6 including 1-mg dexamethasone suppression test, 24-hour urinary free cortisol or late-night
7 salivary cortisol, and it is present in 5 to 78% of patients with PA (19). The large heterogeneity
8 is justified by the differences in the number and type of tests and the different cut-offs adopted
9 in various studies (20). Autonomous and asymmetrical cortisol secretion can cause
10 misinterpretation of the LI, when assessed by A/C LI (13). However, in our study,
11 asymmetrical cortisol production was evident even in patients without autonomous cortisol
12 secretion, suggesting that a confounding effect using cortisol normalization cannot be excluded
13 even in patients with apparently normal cortisol production. On the other side, it should be
14 noted that not all the patients with autonomous cortisol secretion have asymmetrical cortisol
15 secretion (only 36% in our cohort).

16 Theoretically, an asymmetrical production of both hormones (metanephrine and cortisol) can
17 cause the observation of C/M LI \geq 4. However, the fact that cosyntropin stimulation is able to
18 reduce C/M LI in all the patients with C/M LI \geq 4 strongly suggest that these findings are caused
19 by asymmetrical cortisol production.

20 The majority of the patients displayed asymmetrical cortisol secretion homolateral to the side
21 of UPA, suggesting co-secretion of aldosterone and cortisol from the same adenoma/nodule.

22 In 2 cases the asymmetrical cortisol secretion was contralateral to the UPA with CT scan
23 showing bilateral nodules, suggesting the presence of a cortisol secreting nodule on the
24 opposite side of the UPA. This is not surprising, since autonomous cortisol secretion is the
25 most frequent functional abnormality in patients with an adrenal incidentaloma, being observed

1 in up to 20% of cases (20). However, four patients with asymmetrical cortisol secretion had
2 bilaterally normal glands at CT scanning, suggesting that the asymmetrical cortisol production
3 can be the consequence of CT-undetectable micronodules. This observation has an important
4 clinical implication, suggesting that asymmetrical cortisol secretion cannot be ruled out by the
5 presence of bilaterally normal adrenal glands at CT scan.

6 As expected, patients with asymmetrical cortisol secretion displayed the greatest differences in
7 LI defined with A/M LI vs A/C LI, with potential effect on the final diagnosis. However, when
8 LI is close to 4, even a mild asymmetrical cortisol secretion can alter the subtype definition. In
9 order to avoid the bias of asymmetrical cortisol secretion, we proposed the use of A/M LI when
10 AVS is performed under unstimulated conditions. Three patients with UPA defined with A/M
11 LI (but BiPA with A/C LI), showed complete biochemical success after adrenalectomy, while
12 in 5 cases the patients have been treated with medical therapy.

13 Four patients displayed an UPA with A/C LI, but BiPA with A/M LI. One had overt unilateral
14 hypercortisolism and BiPA correctly identified by A/M LI. Two showed complete biochemical
15 success after adrenalectomy, indicating potential missing of UPAs by the use of metanephrine
16 normalization. Both of these patients had a C/M LI \geq 3 on the opposite side of the UPA and
17 increase of A/M LI after cosyntropin stimulation, suggestive of cosyntropin-sensitive APAs.
18 A third patient, who refused adrenalectomy, showed a similar pattern with C/M LI \geq 3 and
19 increase of A/M LI after cosyntropin stimulation. Intriguingly, in all the three patients, the
20 cosyntropin stimulation increased the A/M LI above 4, allowing the correct identification of
21 the UPAs with the stimulated procedure; A/C LI remained $>$ 4 after cosyntropin stimulation.

22 These cases highlight that, in specific scenarios, cosyntropin stimulation can add important
23 information, both with A/M LI and A/C LI, allowing the identification of cosyntropin-sensitive
24 APA that could be otherwise unrecognized. Moreover, cosyntropin stimulation reduces the
25 asymmetrical cortisol secretion, mitigating the interference of cortisol asymmetry when A/C

1 LI is used. On the other side, in some patients with UPA, cosyntropin infusion stimulates
2 aldosterone production from the contralateral gland, reducing A/M LI and A/C LI with
3 incorrect BiPA diagnosis.

4 In summary, the use of metanephrine normalization improves the diagnostic accuracy of
5 unstimulated AVS, avoiding the effects of asymmetrical cortisol secretion and identifying
6 some UPA that are missed with cortisol normalization. On the other hand, the diagnosis of
7 UPA may be missed in few specific cases of cosyntropin-sensitive APA. Cosyntropin
8 administration allows the correct identification of these cases, both with metanephrine and
9 cortisol normalization. However, with cosyntropin administration, some UPA may be missed,
10 due to the stimulation of aldosterone production from the contralateral gland.

11 Since none of the described method is flawless, the evaluation of both, cortisol and
12 metanephrine normalization with unstimulated and cosyntropin stimulated procedures, would
13 be ideal to allow the most accurate definition of subtype diagnosis. Nevertheless, the
14 performance of AVS in two different conditions, would increase the length of the procedure
15 and the complexity of the interpretation.

16 The main limitation of this study is the retrospective design, and consequently the absence of
17 a post-adrenalectomy outcome in some of the patients who had a diagnosis of UPA with A/M
18 LI only. A prospective study, where every patient with UPA diagnosis (defined either with A/C
19 LI or A/M LI) undergoes unilateral adrenalectomy, would be ideal to confirm our results,
20 allowing the identification of true sensitivity and specificity of each normalization method. A
21 second limit of our study is the absence of a systematic screening for autonomous cortisol
22 secretion before AVS.

23 **Conclusion**

24 In this study we reported for the first time the presence of asymmetrical cortisol secretion in
25 18% of patients with PA. We showed that even a mild asymmetrical cortisol secretion can

1 modify the subtype diagnosis using cortisol normalization. The absence of autonomous cortisol
2 secretion or the absence adrenal nodules at CT scanning cannot rule out the presence of
3 asymmetrical cortisol secretion. The use of metanephrine normalization avoids the effect of
4 asymmetrical cortisol secretion, allowing a more accurate definition of PA subtype in the
5 majority of cases.

6
7 **Acknowledgments:** the TESEO-Biobank of Department of Medical Sciences is ISO
8 9001:2015 certified and GDPR compliant, ensuring that pseudonymized samples obtained
9 from consented participants are appropriately identified, and tracked to eliminate the risks of
10 sample misidentification and loss

11
12 **Data Availability:** some or all datasets generated during and/or analyzed during the current
13 study are not publicly available but are available from the corresponding author on reasonable
14 request. Supplemental materials (17) are available at the following link:
15 <https://github.com/CentroIpertenUnito/MetaAVS/raw/main/Supplemental%20Data.pdf>

16

1 References

- 2 1. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L,
3 Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and Clinical
4 Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. *J. Am.*
5 *Coll. Cardiol.* 2017;69(14):1811–1820.
- 6 2. Xu Z, Yang J, Hu J, Song Y, He W, Luo T, Cheng Q, Ma L, Luo R, Fuller PJ, Cai J, Li
7 Q, Yang S, Chongqing Primary Aldosteronism Study (CONPASS) Group. Primary
8 Aldosteronism in Patients in China With Recently Detected Hypertension. *J. Am. Coll.*
9 *Cardiol.* 2020;75(16):1913–1922.
- 10 3. Buffolo F, Monticone S, Tetti M, Mulatero P. Primary aldosteronism in the primary care
11 setting. *Curr Opin Endocrinol Diabetes Obes* 2018;25(3):155–159.
- 12 4. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti
13 G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello M-J, Moretti A,
14 Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina
15 AC, Mantero F, PAPY Study Investigators. A prospective study of the prevalence of
16 primary aldosteronism in 1,125 hypertensive patients. *J. Am. Coll. Cardiol.*
17 2006;48(11):2293–2300.
- 18 5. Mulatero P, Sechi LA, Williams TA, Lenders JWM, Reincke M, Satoh F, Januszewicz
19 A, Naruse M, Doumas M, Veglio F, Wu VC, Widimsky J. Subtype diagnosis, treatment,
20 complications and outcomes of primary aldosteronism and future direction of research:
21 a position statement and consensus of the Working Group on Endocrine Hypertension of
22 the European Society of Hypertension. *J. Hypertens.* 2020;38(10):1929–1936.
- 23 6. Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M-C, Beuschlein F,
24 Rossi GP, Nishikawa T, Morganti A, Seccia TM, Lin Y-H, Fallo F, Widimsky J.
25 Genetics, prevalence, screening and confirmation of primary aldosteronism: a position
26 statement and consensus of the Working Group on Endocrine Hypertension of The
27 European Society of Hypertension. *J. Hypertens.* 2020;38(10):1919–1928.
- 28 7. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M,
29 Young WF. The Management of Primary Aldosteronism: Case Detection, Diagnosis,
30 and Treatment: An Endocrine Society Clinical Practice Guideline. *J. Clin. Endocrinol.*
31 *Metab.* 2016;101(5):1889–1916.
- 32 8. Williams TA, Burrello J, Sechi LA, Fardella CE, Matrozoza J, Adolf C, Baudrand R,
33 Bernardi S, Beuschlein F, Catena C, Doumas M, Fallo F, Giacchetti G, Heinrich DA,
34 Saint-Hilary G, Jansen PM, Januszewicz A, Kocjan T, Nishikawa T, Quinkler M, Satoh
35 F, Umakoshi H, Widimský J, Hahner S, Douma S, Stowasser M, Mulatero P, Reincke
36 M. Computed Tomography and Adrenal Venous Sampling in the Diagnosis of
37 Unilateral Primary Aldosteronism. *Hypertension* 2018;72(3):641–649.
- 38 9. Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, Izawa S, Ichijo T,
39 Otsuki M, Omura M, Ogawa Y, Oki Y, Kurihara I, Kobayashi H, Sakamoto R, Satoh F,
40 Takeda Y, Tanaka T, Tamura K, Tsuiki M, Hashimoto S, Hasegawa T, Yoshimoto T,
41 Yoneda T, Yamamoto K, Rakugi H, Wada N, Saiki A, Ohno Y, Haze T. Japan

- 1 Endocrine Society clinical practice guideline for the diagnosis and management of
2 primary aldosteronism 2021. *Endocr J* 2022;69(4):327–359.
- 3 10. Wannachalee T, Caoili E, Nanba K, Nanba A, Rainey WE, Shields JJ, Turcu AF. The
4 Concordance Between Imaging and Adrenal Vein Sampling Varies With Aldosterone-
5 Driver Somatic Mutation. *J Clin Endocrinol Metab* 2020;105(10):e3628-3637.
- 6 11. Buffolo F, Monticone S, Williams T, Rossato D, Burrello J, Tetti M, Veglio F, Mulatero
7 P. Subtype diagnosis of primary aldosteronism: is adrenal vein sampling always
8 necessary? *Int J Mol Sci* 2017;18(4):848.
- 9 12. Dekkers T, Deinum J, Schultzekool LJ, Blondin D, Vonend O, Hermus ARRM,
10 Peitzsch M, Rump LC, Antoch G, Sweep FCGJ, Bornstein SR, Lenders JWM,
11 Willenberg HS, Eisenhofer G. Plasma metanephrine for assessing the selectivity of
12 adrenal venous sampling. *Hypertension* 2013;62(6):1152–1157.
- 13 13. Goupil R, Wolley M, Ungerer J, McWhinney B, Mukai K, Naruse M, Gordon RD,
14 Stowasser M. Use of plasma metanephrine to aid adrenal venous sampling in combined
15 aldosterone and cortisol over-secretion. *Endocrinol Diabetes Metab Case Rep*
16 2015;2015:150075.
- 17 14. Ceolotto G, Antonelli G, Caroccia B, Battistel M, Barbiero G, Plebani M, Rossi GP.
18 Comparison of Cortisol, Androstenedione and Metanephrines to Assess Selectivity and
19 Lateralization of Adrenal Vein Sampling in Primary Aldosteronism. *J Clin Med*
20 2021;10(20):4755.
- 21 15. Christou F, Pivin E, Denys A, Abid KA, Zingg T, Matter M, Pechère-Bertschi A,
22 Maillard M, Grouzmann E, Wuerzner G. Accurate Location of Catheter Tip With the
23 Free-to-Total Metanephrine Ratio During Adrenal Vein Sampling. *Front Endocrinol*
24 (*Lausanne*) 2022;13:842968.
- 25 16. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role
26 for adrenal venous sampling in primary aldosteronism. *Surgery* 2004;136(6):1227–
27 1235.
- 28 17. Buffolo F, Pieroni J, Ponzetto F, Forestiero V, R, Rossato D, Fonio P, Nonnato A,
29 Settanni F, Mulatero P, Mengozzi G, Monticone S. Data from: Prevalence of cortisol
30 co-secretion in patients with primary aldosteronism: role of metanephrine in adrenal
31 vein sampling. *GitHub* 2023; Deposited March 6th, 2023.
- 32 18. Williams TA, Gomez-Sanchez CE, Rainey WE, Giordano TJ, Lam AK, Marker A, Mete
33 O, Yamazaki Y, Zerbini MCN, Beuschlein F, Satoh F, Burrello J, Schneider H, Lenders
34 JWM, Mulatero P, Castellano I, Knösel T, Papotti M, Saeger W, Sasano H, Reincke M.
35 International Histopathology Consensus for Unilateral Primary Aldosteronism. *J Clin*
36 *Endocrinol Metab* 2021;106(1):42–54.
- 37 19. Inoue K, Kitamoto T, Tsurutani Y, Saito J, Omura M, Nishikawa T. Cortisol Co-
38 Secretion and Clinical Usefulness of ACTH Stimulation Test in Primary Aldosteronism:
39 A Systematic Review and Biases in Epidemiological Studies. *Front Endocrinol*
40 2021;12:645488.

20. Sherlock M, Scarsbrook A, Abbas A, Fraser S, Limumpornpetch P, Dineen R, Stewart PM. Adrenal Incidentaloma. *Endocr Rev* 2020;41(6):bnaa008.

Legends to figures

Figure 1. The Bland-Altman plot (A) shows the correlation between A/M LI and A/C LI for unstimulated AVS (n=88). The y-axis reports the ratio between A/M LI and A/C LI, while the x-axis reports the mean value of A/M LI and A/C LI. The plot highlights that patients with asymmetrical cortisol secretion (black dots) show greater dissimilarity between A/M LI or A/C LI than patients with symmetrical cortisol secretion (gray dots). The panel (B) shows C/M LI with and without cosyntropin stimulation in patients that performed both procedures and showed asymmetrical cortisol secretion with unstimulated procedure (n=11); * indicates an AVS where the dominant side of C/M LI changed after cosyntropin stimulation. The pie charts show the prevalence of asymmetrical cortisol secretion defined as C/M LI ≥ 4 (C) and the distribution of C/M LI compared to the subtype diagnosis (D). A/C LI; aldosterone to cortisol lateralization index; A/M LI: aldosterone/metanephrine lateralization index; AVS: adrenal venous sampling; BiPA: bilateral primary aldosteronism; C/M LI: cortisol to metanephrine lateralization index; UPA; unilateral primary aldosteronism.

Figure 2. The Bland-Altman plot (A) shows the correlation between A/M LI and A/C LI for unstimulated AVS (n=88). The y-axis reports the ratio between A/M LI and A/C LI, while the x-axis reports the mean value of A/M LI and A/C LI. The scatterplot (B) shows A/M LI and A/C LI for unstimulated AVS (n=88), highlighting the final diagnosis according to A/M LI or A/C LI. In both plots, we highlighted patients with a different subtype diagnosis (black dots) and those with a similar diagnosis (gray dots). The pie chart (C) reports the proportion of patients with unilateral PA that show an increase or reduction of A/M LI after cosyntropin stimulation. The panel (D) show peripheral aldosterone changes after cosyntropin stimulation


1 in the subgroup of patients with A/M LI increase after cosyntropin stimulation vs patients with
 2 A/M LI reduction. *P-value is considered significant for $p < 0.05$. A/C LI; aldosterone to cortisol
 3 lateralization index; A/M LI: aldosterone/metanephrine lateralization index; AVS: adrenal
 4 venous sampling; BiPA: bilateral primary aldosteronism; C/M LI: cortisol to metanephrine
 5 lateralization index; LI: lateralization index; PA; primary aldosteronism.

7 **Table 1.** Clinical and biochemical parameters

Variables	Patients (n=101)
Age at screening (years)	50±9
Female sex, n (%)	37 (36.6%)
Systolic BP (mmHg)	157±19
Diastolic BP (mmHg)	96±11
BMI (Kg/sqm)	26.3±3.8
Lowest Potassium (mEq/L)	3.4±0.6
Creatinine (mg/dL)	0.88±0.20
Diabetes, n (%)	6 (5.9)
PRA (ng/mL/h) (n=88)	0.20 (0.10-0.40)
Renin (mU/L) (n=13)	1.80 (0.55-3.75)
Aldosterone (ng/dL)	33.4 (24.0-45.4)
Adrenal Vein Sampling (%)	
Unstimulated	49 (48.5)
Unstimulated and cosyntropin stimulated	52 (51.5)

Subtype diagnosis (%)	
Unilateral PA	50 (49.5)
Bilateral PA	35 (34.7)
Undetermined	16 (15.8)

- 1 Values are mean \pm SD, median (IQR), or absolute number (%).
- 2 Abbreviations: BP, blood pressure; BMI, body mass index; PA, primary aldosteronism; PRA,
- 3 plasma renin activity.
- 4
- 5



6
7
8

Figure 1
339x200 mm (x DPI)




Figure 2
339x260 mm (x DPI)

1
2
3